ALLO allogene.com: Enterprise Value to EBITDA Ratio

allogene.com (ALLO) - corporate logo

Allogene Therapeutics (ALLO) is a pioneer in developing allogeneic cancer therapies, providing immediate access to treatment via donor cells. This approach transforms a complex process into a scalable product. This EV/EBITDA chart reflects a current valuation of 0.00. High barriers to entry and patent protection, combined with FDA requirements, provide the company with a significant technological advantage.

Allogene Therapeutics, Inc. - ALLO Enterprise Value to EBITDA Ratio (period 11/23/2025 - 11/12/2026)

allogene.com (ALLO) - metric breakdowns and financial figures

- stock price and consensus target price:
Stock Quotes Allogene Therapeutics Inc|ALLO - Average Forecast Price
- company stock capitalization data:
Market Valuation Allogene Corp|ALLO - Value Adjusted for Debt and Cash
- business book valuation details:
Book Value per Share Allogene|ALLO - Company Net Assets|Market Capitalization to Book Value Ratio allogene.com|ALLO - Company Assets
- debt and solvency information:
Debt to Equity Allogene Therapeutics|ALLO - Long-Term Debt to Equity|Short-Term Debt to Equity Allogene|ALLO - Company Debts|Debt to Book Value Allogene Corp|ALLO - Company Long-Term Loans and Borrowings|Company Short-Term Debts Allogene|Quick Ratio allogene.com
- financial results and valuation multiples details:
ALLO - Company Net Income|Expected Profit Allogene Therapeutics|ALLO - Price to Earnings Multiple|Forward P/E Multiple Allogene Therapeutics|ALLO - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio Allogene Corp|ALLO - Income before deduction of interest, taxes and amortization|Net earnings per share for the last 12 months Allogene|ALLO - Earnings per share for the last four quarters|Quarterly EPS earnings growth allogene.com|ALLO - Earnings per share increase in current year|Earnings growth forecast for next year Allogene Therapeutics
Summary company analytics:Allogene Therapeutics Inc (ALLO)
Original product of Allogene

The EV/EBITDA multiple determines the value of a business relative to its operating profit before depreciation, taxes, and interest. By analyzing the EV/EBITDA valuation trend, an investor sees the ratio of market capitalization plus debt to the ability to generate cash flow. This indicator measures the payback period of assets, accounting for the debt load. For Allogene Therapeutics (ALLO), this is a critical metric reflecting the cost of developing affordable allogeneic CAR-T therapy.

Key competitors

Legend Biotech Inc. - Enterprise Value to EBITDA Ratio|Sana Corp (SANA) - Company Value to EBITDA|AUTL: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation RNAC (selectabio.com)|CLLS: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Caribou Biosciences Inc.|TIL (Instil Bio, Inc) - EV/EBITDA Multiple|Company Value to EBITDA Genenta GNTA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Century Therapeutics (IPSC)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization JSPR (jaspertherapeutics.com)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Senti Biosciences SNTI|Adaptimmune Therapeutics plc - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CERO: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation TCRT (Alaunos Therapeutics)|ACHL: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple cargo-tx.com CRGX|PSTX (Poseida Therapeutics, Inc.) - EV/EBITDA Multiple|Company Value to EBITDA 2seventy bio Inc. TSVT|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Gracell Biotechnologies Ltd (GRCL)